Liposome-mediated Induction of Apoptosis of Human Hepatoma Cells by C-Myc Antisense Phosphorothioate Oligodeoxynucleotide and 5-Fluorouracil

Yuan, Yuan; Cai, Hui; Yang, Xiaojun; Li, Wei; He, Jin; Guo, Tiankang; Chen, Yirong

doi:10.7314/apjcp.2014.15.14.5529

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, because ASODNs exhibit poor solubility, low affinity for their target complementary RNA sequences (21), phosphorothioate modification was adopted for ASODN in the current study. PS-ASODN presents with good aqueous solubility, increased resistance to degradation of oligodeoxynucleotide by nuclease, increased stability and liposome encapsulation (7,22). Previous studies have demonstrated that PS-ASOND suppressed the activity of telomerase and tumor growth (23)(24)(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Cao

Chen

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Emergence of resistance, unavoidable systemic toxicity and unsatisfactory efficacy arethe main obstacles for traditional cancer therapy. Combination with phosphorothioate modified antisense oligonucleotides (PS‑ASODN) against human telomerase reverse transcriptase (hTERT) may enhance the therapeutic effect of irradiation. However, the effect of PS‑ASODN against hTERT on the anti‑tumor effects of irradiation in liver cancer remain unclear. In the current study, Walker 256 cells were transfected with hTERT PS‑ASODN. Cell proliferation and cell viability were measured using the MTT assay and cell senescence was examined by SA‑β‑gal staining. Telomerase activity was determined by telomeric repeat amplification protocol‑polymerase chain reaction‑ELISA. Cell apoptosis was assayed by flow cytometry and DNA damage was determined by the comet assay.The PS‑ASODN was demonstrated to have an inhibitory effect on cell proliferation and accelerated effect on cell senescence by inhibiting telomerase activity. PS‑ASODN promoted the irradiation‑induced inhibition of cell viability and telomerase activity, and irradiation‑induced DNA damage and cell apoptosis via the activation of apoptosis‑associated proteins. Taken together, these results indicated that combined treatment of PS‑ASODN with irradiation significantly enhanced tumor inhibition. Therefore, PS‑ASODN provides an experimental foundation for gene therapy and is proposed for application in clinical treatment of liver cancer combined with radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Cao

Chen

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…MYC promotes tumorigenesis by inducing proliferation, blocking differentiation, and promoting self-renewal (Dang, 2012;Gabay et al, 2014). Thus, treatment with Myc-ASO reduces cell proliferation and induces apoptosis, thus reducing tumor growth and invasion (Li et al, 2011b;Yuan et al, 2014;Dhanasekaran et al, 2020). ADP-ribosylation factor-like 4C (ARL4C) is a member of the small GTP-binding protein family and plays a role in tumor genesis and development.…”

Section: Application Of Antisense Oligonucleotide In Liver Cancermentioning

confidence: 99%

Antisense oligonucleotide is a promising intervention for liver diseases

Fan

Zou

2022

Front. Pharmacol.

View full text Add to dashboard Cite

As the body’s critical metabolic organ, the liver plays an essential role in maintaining proper body homeostasis. However, as people’s living standards have improved and the number of unhealthy lifestyles has increased, the liver has become overburdened. These have made liver disease one of the leading causes of death worldwide. Under the influence of adverse factors, liver disease progresses from simple steatosis to hepatitis, to liver fibrosis, and finally to cirrhosis and cancer, followed by increased mortality. Until now, there has been a lack of accepted effective treatments for liver disease. Based on current research, antisense oligonucleotide (ASO), as an alternative intervention for liver diseases, is expected to be an effective treatment due to its high efficiency, low toxicity, low dosage, strong specificity, and additional positive characteristics. In this review, we will first introduce the design, modification, delivery, and the mechanisms of ASO, and then summarize the application of ASO in liver disease treatment, including in non-alcoholic fatty liver disease (NAFLD), hepatitis, liver fibrosis, and liver cancer. Finally, we discuss challenges and perspectives on the transfer of ASO drugs into clinical use. This review provides a current and comprehensive understanding of the integrative and systematic functions of ASO for its use in liver disease.

show abstract

Liposome-mediated Induction of Apoptosis of Human Hepatoma Cells by C-Myc Antisense Phosphorothioate Oligodeoxynucleotide and 5-Fluorouracil

Cited by 2 publications

References 18 publications

Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Antisense oligonucleotide is a promising intervention for liver diseases

Contact Info

Product

Resources

About